Trevi Therapeutics
TRVI
13.35
-0.37
-2.70%
Trevi Therapeutics
US · TRVI
#2810 by market cap
Listed 2019
13.35
-0.37
-2.70%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
- Total institutional ownership rose 3.4 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 111.77% +3.43pp
- Institutions
- 260 +5
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund57.69%
VC/PE Fund29.46%
Hedge Fund18.70%
Public Company3.89%
Private Company0.79%
Individual/Insider0.70%
Family Office/Trust0.40%
Insurance Company0.33%
Government Pension Fund0.28%
Top holders as of 2026-09-30
FMR
9.56% · 13.63M sh
New Enterprise Associates, Inc.
9.28% · 13.22M sh
BlackRock
8.62% · 12.29M sh
Frazier Life Sciences Management, LP
6.97% · 9.94M sh
Vanguard Capital Management, LLC
4.29% · 6.11M sh
Wellington Management Group
3.99% · 5.68M sh
Vivo Capital, LLC
3.57% · 5.09M sh
Woodline Partners LP
2.86% · 4.08M sh
Assenagon Asset Management S.A.
2.47% · 3.53M sh
MPM BioImpact LLC
2.16% · 3.07M sh
Vestal Point Capital, LP
2.18% · 3.10M sh
State Street Global Advisors
2.30% · 3.27M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 12 sells
| Name | Role | Stake |
|---|---|---|
| David Meeker | Independent Chairperson | 0.25% |
| Thomas Sciascia | Co-Founder & CSO | 0.16% |
| Jennifer Good | Co-Founder, CEO, President, & Director | 0.15% |
| Farrell Simon | Chief Commercial Officer | 0.06% |
| Lisa Delfini | Former Chief Financial Officer | 0.05% |
| Christopher Galletta | Controller & Chief Accounting Officer | 0.02% |
| Anne VanLent | Independent Director | 0.02% |
| Michael Heffernan | Independent Director | 0.00% |
| New Enterprise Associates, Inc. | -- | -- |
| James Cassella | Chief Development Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Michael Heffernan | Independent Director | Derivative Exercise and Sale | -39,473 | $3.04–15.88 |
| 2026-06-02 | Anne VanLent | Independent Director | Other Derivative Acquisition | +35,000 | $13.45 |
| 2026-06-02 | Dominick Colangelo | Independent Director | Other Derivative Acquisition | +35,000 | $13.45 |
| 2026-06-02 | Edward Mathers | Independent Director | Other Derivative Acquisition | +35,000 | $13.45 |
| 2026-06-02 | David Meeker | Independent Chairperson | Other Derivative Acquisition | +35,000 | $13.45 |
| 2026-06-02 | Michael Heffernan | Independent Director | Other Derivative Acquisition | +35,000 | $13.45 |
| 2026-02-18 | James Cassella | Chief Development Officer | Other Derivative Acquisition | +215,000 | $10.56 |
| 2026-02-18 | Jennifer Good | Co-Founder, CEO, President, & Director | Other Derivative Acquisition | +675,000 | $10.56 |
| 2026-02-18 | Thomas Sciascia | Co-Founder & CSO | Other Derivative Acquisition | +85,000 | $10.56 |
| 2026-02-18 | Christopher Galletta | Controller & Chief Accounting Officer | Other Derivative Acquisition | +35,000 | $10.56 |
| 2026-02-18 | Farrell Simon | Chief Commercial Officer | Other Derivative Acquisition | +160,000 | $10.56 |
| 2026-01-07 | David Hastings | Chief Financial Officer & Principal Financial Officer | Other Derivative Acquisition | +375,000 | $11.21 |
| 2025-12-01 | Christopher Galletta | Controller & Chief Accounting Officer | Derivative Exercise and Retained | +4,225 | $0.51 |
| 2025-10-06 | Lisa Delfini | Former Chief Financial Officer | Intent to Sell (Form 144) | -108,650 | $9.50 |
| 2025-10-02 | Lisa Delfini | Former Chief Financial Officer | Intent to Sell (Form 144) | -40,000 | $9.67 |
| 2025-08-26 | Lisa Delfini | Former Chief Financial Officer | Intent to Sell (Form 144) | -312,855 | $8.09 |
| 2025-06-10 | Anne VanLent | Independent Director | Other Derivative Acquisition | +45,000 | $6.25 |
| 2025-06-10 | Dominick Colangelo | Independent Director | Other Derivative Acquisition | +45,000 | $6.25 |
| 2025-06-10 | Edward Mathers | Independent Director | Other Derivative Acquisition | +45,000 | $6.25 |
| 2025-06-10 | David Meeker | Independent Chairperson | Other Derivative Acquisition | +45,000 | $6.25 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.
Trevi Therapeutics discussion 0 comments